Welcome to our dedicated page for Trevena news (Ticker: TRVN), a resource for investors and traders seeking the latest updates and insights on Trevena stock.
Trevena, Inc. (TRVN) is a biopharmaceutical company focused on medicines for central nervous system (CNS) disorders, and its news flow reflects both clinical and corporate developments. Company press releases highlight progress with its approved product OLINVYK (oliceridine) injection for acute pain in adults and its pipeline of investigational CNS candidates, including TRV045, TRV250 and TRV734.
News updates frequently cover clinical and preclinical data for TRV045, a highly selective S1P1 receptor modulator in development for neuropathic pain secondary to diabetic peripheral neuropathy and under exploration for epilepsy through collaborations such as the NIH-supported Epilepsy Therapy Screening Program. Trevena reports results from proof-of-concept studies, preclinical pain and epilepsy models, and ongoing formulation and toxicology work that inform the potential path toward later-stage development.
Investors can also follow commercial and strategic updates related to OLINVYK, including reductions in commercial support, strategic reviews of alternatives for the product, and discussions of how OLINVYK remains available for purchase while the company evaluates options such as sale, license, divestiture or discontinuation of U.S. commercial sales.
Trevena’s news includes capital markets and corporate actions, such as private placements, warrant exercises, royalty-based financing amendments, and a 1-for-25 reverse stock split. The company has reported decisions by the Nasdaq Hearings Panel to delist its common stock, the suspension of trading on Nasdaq, and the commencement of trading on the OTC Pink Open Market and subsequent identification of the OTC Expert Market as the trading venue in SEC filings.
For readers tracking TRVN, the news stream provides context on clinical progress, regulatory and safety information for OLINVYK, financing arrangements, cost-cutting measures, board and management changes, and the company’s ongoing strategic review of its assets.
Trevena, Inc. (Nasdaq: TRVN) announced the initiation of a Phase 1 proof-of-concept study for TRV045, a novel sphingosine-1-phosphate receptor modulator, aiming to treat epilepsy and CNS disorders. The randomized, double-blind study will assess TRV045's impact on brain function using Transcranial Magnetic Stimulation, with enrollment expected to complete by mid-2023. Preliminary data from this study, along with another ongoing trial, are anticipated later this year. TRV045 has previously shown potential for alleviating diabetic neuropathic pain without significant side effects. The company’s pipeline includes additional investigational drug candidates.
Trevena, Inc. (Nasdaq: TRVN) announced the publication of data on OLINVYK in the peer-reviewed journal Anesthesiology on February 14, 2023. The study highlights OLINVYK's reduced impact on respiratory depression compared to IV morphine in elderly and overweight patients. Findings from a double-blind, randomized crossover study involving 18 participants showed that oliceridine provided a more rapid onset of respiratory depression, but with a smaller magnitude over time. Adverse events were similar between both opioids, with dizziness and lightheadedness being the most reported. This research may influence clinical practices for managing acute pain in older patients.
Trevena, Inc. (Nasdaq: TRVN) announced the enrollment of the first subject in a Phase 1 clinical study for TRV045, a novel S1P receptor modulator targeting CNS disorders. This randomized, double-blind, placebo-controlled study will evaluate TRV045’s mechanism of action and potential anti-inflammatory effects in 24 healthy volunteers through multiple dosing. The trial aims to assess the drug's efficacy in treating neuropathic pain and epilepsy. The study started in December 2022 and is expected to complete enrollment by mid-2023.
Trevena, Inc. (Nasdaq: TRVN) presented three abstracts at recent medical meetings, highlighting advancements in its clinical pipeline.
Key findings include TRV045's efficacy in reducing seizure burden in nonclinical epilepsy models and OLINVYK's reduced neurocognitive effects compared to morphine, along with its lower incidence of gastrointestinal side effects compared to hydromorphone and fentanyl.
These results support Trevena's ongoing development of innovative treatments for central nervous system disorders.
Trevena, Inc. (Nasdaq: TRVN) has announced that it has regained compliance with Nasdaq's minimum bid price requirement. This notice was received on November 28, 2022, confirming that the company maintained a closing bid price of $1.00 or more for at least 10 consecutive trading days. As a result, Trevena’s common stock will continue to be listed on the Nasdaq Capital Market. Trevena develops innovative medicines for central nervous system disorders and has one approved product in the U.S., OLINVYK (oliceridine) injection.
Trevena, Inc. (Nasdaq: TRVN) has announced a registered direct offering of 2,614,380 shares of common stock and warrants, priced at $3.06 per share. The total gross proceeds are expected to be approximately $8.0 million, intended for general corporate purposes, including working capital. The offering will close around November 18, 2022, pending customary conditions. H.C. Wainwright & Co. is the exclusive placement agent. This offering is made under a previously filed shelf registration statement with the SEC.
Trevena, Inc. (Nasdaq: TRVN) announced a 1-for-25 reverse stock split effective November 9, 2022, at 5:01 p.m. ET. This move aims to comply with the $1.00 minimum bid price for Nasdaq listing. The reverse stock split was sanctioned by stockholders on September 8, 2022. Following the split, the trading of Trevena's common stock will commence on a split-adjusted basis on November 10, 2022. The action will consolidate shares without changing the par value and will affect stock options and warrants. Stockholders entitled to fractional shares will receive cash compensation.
Trevena, Inc. (Nasdaq: TRVN) announced positive results from a Phase 1 study of TRV045, a selective S1P1 receptor modulator. The trial involved 53 healthy volunteers and demonstrated a favorable tolerability profile with no serious adverse events. The pharmacokinetic (PK) profile supports anticipated once-daily dosing. Nonclinical studies indicated TRV045's potential as a disease-modifying treatment for epilepsy based on anti-inflammatory effects observed in astrocytes. The company plans additional studies to further validate the drug's efficacy in treating diabetic neuropathic pain and epilepsy.
Trevena reported significant progress in the commercialization of OLINVYK with the receipt of CMS pass-through reimbursement, enhancing its usage in outpatient settings. The company has also entered a multi-year agreement with Vizient for broad access to OLINVYK. Additionally, Trevena announced positive topline results for TRV045, a novel S1P receptor modulator, indicating safety and tolerability for chronic pain and epilepsy treatment. Financially, the company reported a net loss of $15.3 million in Q3 2022 but holds $40.4 million in cash to fund operations into Q3 2023.
Trevena, Inc. (Nasdaq: TRVN) will announce its third quarter financial results on November 9, 2022, before market open. The company, focused on CNS disorder treatments, will host a conference call at 8:00 a.m. ET the same day, featuring key executives including CEO Carrie Bourdow and CFO Barry Shin. Trevena currently has one approved product, OLINVYK, for managing acute pain, and a pipeline of promising investigational drugs for various conditions including diabetic neuropathic pain and migraine. More information is available on their website.